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Objectives. This open-label trial assessed the eﬃcacy and safety of rifaximin as ﬁrst-line therapy in hospitalized patients with
Clostridium diﬃcile-associated diarrhea (CDAD). Methods. We enrolled thirteen patients who had a conﬁrmed diagnosis of CDAD
characterized by ≥3 unformed stools/day and positive C. diﬃcile toxin assay. Those patients received rifaximin 400mg three times
daily for 10 days. Resolution of symptoms, repeat assay 10 days after treatment, and followup for recurrence were assessed. Results.
Eight patients completed the study, and all reported symptom resolution during treatment. Mean time to last unformed stool was
132h ± 42.5h. Seven patients had no relapse by week 2 and in longer followup (median 162 days). One patient had recurrent
CDAD during a repeat hospitalization. Conclusions. Rifaximin was eﬀective and safe as ﬁrst-line treatment for CDAD and did not
result in recurrence in most patients.
1.Introduction
Clostridium diﬃcile infection is one of the most common
causes of nosocomial diarrhea and may be associated with
substantial morbidity and mortality [1–3]. The prevalence
and severity of C. diﬃcile-associated diarrhea (CDAD)
have been increasing since the mid-1990s [4, 5]. These
epidemiologic changes may be related to the emergence of
virulent, epidemic strains of C. diﬃcile, particularly strains
with binary toxin genes characterized as BI/NAP1, that have
been implicated in multiple CDAD outbreaks in North
America and Europe [3, 6, 7]. These previously uncommon
C.diﬃcilestrainsproducesubstantiallyhigherlevelsoftoxins
A and B than other hospital-acquired C. diﬃcile strains [7],
are highly resistant to ﬂuoroquinolone antibiotics [3, 6, 8],
and may be associated with increased disease severity and
mortality [3, 9].
Metronidazole and vancomycin are most commonly
administered for the treatment of CDAD and represent the
current standard of care [5, 10]. Metronidazole is generally
considered ﬁrst-line therapy [10, 11]. However, in addition
to having the potential for adverse eﬀects (e.g., nausea,
vomiting,metallictaste),metronidazoleisalmostcompletely
absorbed in the intestine and is present in low and variable
levels in feces, suggesting that it may have limited direct
action in the colon [10–12]. Because vancomycin is more
expensive than metronidazole and may promote the growth
of vancomycin-resistant enterococci, it is usually reserved
for the treatment of severe CDAD or use in certain patient
populations, such as pregnant women and those who are
unresponsive to or unable to tolerate oral metronidazole
[1, 11]. Furthermore, CDAD symptoms are unresponsive to
metronidazole or vancomycin in as many as 25% of treated
patients [13, 14], and up to 29% of patients experience
symptom recurrence after initial successful treatment with
either of these agents [14, 15]. Recurrence normally occurs
within 2 weeks after completion of treatment. These data,
along with reports of increasing recurrence rates after
treatmentwithmetronidazoleorvancomycininthepresence
of decreasing bacterial susceptibility to these antibiotics [16,
17],havepromptedinvestigationofnewtherapiesforCDAD.2 Gastroenterology Research and Practice
Rifaximin is a rifamycin derivative characterized by
a broad antimicrobial spectrum; it has activity against
most Gram-negative and Gram-positive bacteria, as well
as anaerobes and aerobes [18, 19]. When administered
orally, rifaximin is virtually nonabsorbed (<0.4%) and exerts
activity almost entirely within the intestinal lumen [20].
I nv i t r os t u d i e sh a v es h o w nr i f a x i m i nt oh a v eh i g hl e v e l s
of activity against multiple C. diﬃcile isolates, including
recent epidemic strains, with a 90% minimum inhibitory
concentration of 0.015µg/mL and relatively low incidence
of spontaneous resistance to C. diﬃcile [21, 22]. Rifaximin
has been extensively studied in numerous countries for
the treatment of various conditions, including acute bac-
terial diarrhea, intestinal bacterial overgrowth, and hepatic
encephalopathy, and is licensed in the United States for the
treatmentoftravelers’diarrheacausedbynoninvasivestrains
of Escherichia coli [19, 23].
Several small clinical studies with ≤8 patients [24, 25]
and single-patient case reports [26, 27]h a v ep r o v i d e d
encouraging results using rifaximin for treating recurrent or
refractory CDAD and preventing recurrence after successful
treatment with vancomycin. However, data regarding the
potential eﬃcacy of rifaximin as initial therapy for CDAD
are limited. A randomized study with 20 patients who
received rifaximin 600mg/d or vancomycin 1g/d for 10 days
demonstrated rifaximin to be as eﬀective as vancomycin
for resolving diarrhea [28]. An industry-sponsored larger
prospective trial of rifaximin for CDAD (NCT 00269399)
was discontinued due to diﬃculties with enrollment. This
prospective, open-label study evaluated the eﬃcacy and
safety of rifaximin as a ﬁrst-line treatment for CDAD in
hospitalized patients in a university hospital setting.
2. Methods
This open-label pilot study was conducted at a single
academic medical center of 400 beds and approximately
5–12 inpatient C. diﬃcile tests ordered per day (source,
personal communications: University of Chicago Infection
Control Oﬃce and Microbiology Laboratory). Consecutive
hospitalized patients >18 years of age with C. diﬃcile infec-
tion were identiﬁed by referral from attending physicians
or the hospital microbiology laboratory between January
2006 and October 2006 (a predeﬁned study recruitment
duration). Eligible patients had acute diarrhea (deﬁned as
≥3 unformed stools during a 24-hour period) and a stool
enzyme immunoassay (EIA) result positive for C. diﬃcile
toxinAorB.Patientswereexcludediftheyhadinﬂammatory
bowel disease or microscopic colitis; symptoms suggesting
moderate or severe dehydration (e.g., orthostasis); symp-
toms associated with fulminant colitis or toxic megacolon,
including colon distention >10cm on radiograph, peritoneal
signs of rebound, or abdominal guarding due to colitis;
received metronidazole or oral vancomycin within 2 days
before recruitment or received >2 doses of an antidiarrheal
agent within 8 hours before recruitment. Patients with feed-
ingtubesandfemalepatientswithnomensesforgreaterthan
14 days prior to enrollment were also excluded. All patients
provided written informed consent before receiving study
treatment. The study protocol and informed consent form
were approved by the University of Chicago Institutional
Review Board.
Patients who met inclusion criteria received oral rifax-
imin (Xifaxan; Salix Pharmaceuticals, Inc, Morrisville, NC)
400mg three times daily for 10 days. Patients were instructed
to complete daily entries on a stool diary card to document
the frequency and consistency of bowel movements during
the treatment period. Stools were characterized as formed if
they retained their shape or unformed if they took the shape
of their container or could be poured. Patients recorded
in a stool diary the date, time, and stool consistency after
eachbowelmovement.Duringthetreatmentperiod,patients
werevisiteddailywhileinthehospitalortelephonedathome
after discharge to ensure protocol compliance and monitor
for adverse events. Stool samples for repeat EIA analysis
were collected 10 days after rifaximin treatment. Patients
were contacted via telephone 2 weeks after completion of
rifaximin therapy and up to 180 days later per protocol to
assess short- and long-term symptom relapse, deﬁned as ≥3
unformed stools per day.
The primary endpoint was time from ingestion of the
ﬁrst dose of rifaximin to symptom resolution. Secondary
endpoints included time to last unformed stool (TLUS),
numberoftreatmentfailures,eradicationoftoxininthestool
as determined by negative stool EIA result immediately after
rifaximin treatment, relapse rates, and adverse events.
3. Results
Thirteen consecutive hospitalized patients with CDAD who
met eligibility criteria were enrolled and began treatment
with rifaximin per protocol. Five of these 13 patients did
not complete the treatment course and were excluded from
analysis: 1 patient developed hypercapnic respiratory failure
unrelated to the study treatment, 1 patient voluntarily
withdrew after transfer to an extended care facility, and 3
patients violated protocol. Of the protocol violations, two
did not take rifaximin as instructed and 1 subject was lost
to followup despite numerous attempts to contact her. None
were due to side eﬀects during the time on observed therapy.
Eightpatients(meanage,55y;range,39–76y)completed
the protocol and received rifaximin 1200mg/d for 10 days
(Table 1). Of these 8 patients, 7 had no prior history
of CDAD. The patient with previous history of CDAD
had a history of endometrial cancer and was receiving
chemotherapy. She had three recurrences of CDAD before
hospitalization and was symptomatic upon admission; prior
treatments included metronidazole and vancomycin.
All of the 8 patients who completed rifaximin treatment
achieved symptom resolution, with an overall mean TLUS of
151 hours (range, 84–282h; Table 2). Of these 8 patients, 7
(88%) had symptom resolution during the prespeciﬁed 10-
day treatment period (primary endpoint). The mean TLUS
of these 7 patients was 132h (range, 84–192h). One patient
with endometrial cancer completed 10 days of treatment but
achieved symptom resolution at day 12 of followup.Gastroenterology Research and Practice 3
Table 1: Patient demographics and characteristics.
Patient Age Sex Reason for hospitalization Comorbidities Previous CDAD
(1) 68 F Deep vein thrombosis
Hypertension, CRI, nonsmall cell lung
cancer, aortic valve repair, Hodgkin’s
lymphoma
No
(2) 62 F Neutropenic fever and reinduction of
chemotherapy
Acute myelogenous leukemia,
hypertension, uterine cancer, history of
VRE
Yes
(3) 68 F Acute renal failure, volume depletion Breast cancer, COPD, CHF, MGUS,
Klebsiella pneumonia infection, anemia No
(4) 41 M CHF exacerbation (ejection fraction 15%) Congenital cardiomyopathy; CRI No
(5) 76 F Pneumonia hypertension, diabetes mellitus, ESRD No
(6) 46 M Diverticulitis requiring partial colectomy Hypertension, umbilical hernia No
(7) 39 M Diarrhea, volume depletion Right inguinal hernia No
(8) 39 M Failure to thrive Extramedullary CML, graft-versus-host
disease, pleural eﬀusions, depression No
CDAD: Clostridium diﬃcile-associated diarrhea; CHF: chronic heart failure; CML: chronic myeloid leukemia; COPD: chronic obstructive pulmonary disease;
CRI: chronic renal insuﬃciency; ESRD: end-stage renal disease; MGUS: monoclonal gammopathy of unknown signiﬁcance; VRE: vancomycin-resistant
Enterococcus.
Table 2: CDAD symptom improvement with rifaximin 1200mg/day for 10 days.
Patient Symptom resolution
with rifaximin TLUS, h∗ Followup stool EIA† Relapse at 2 weeks Relapse (followup, d)
(1) Yes 84 NA‡ No No (261)
(2) Yes‡ 282 Positive Yes NA
(3) Yes 128 Negative No No (194)
(4) Yes 108 Negative No Yes (52)
(5) Yes 187 Negative No No (162)
(6) Yes 96 Positive No No (149)
(7) Yes 192 Negative No No (160)
(8) Yes 131 Negative No No (36)
CDAD: Clostridium diﬃcile-associated diarrhea; EIA: enzyme immunoassay; NA: not applicable; TLUS: time to last unformed stool.
∗From ingestion of ﬁrst rifaximin tablet. †Obtained on day 10 following initiation of rifaximin therapy. ‡Followup stool sample not provided. ‡Symptom
resolution occurred 2 days after completing the 10-day course of therapy.
Rifaximin was well tolerated, with no drug-related
adverse events reported during the rifaximin treatment
period.
Stool samples for followup analysis were available for
7 patients; 5 of these 7 patients had stool EIA results
negative for C. diﬃcile toxin 10 days after initiating rifaximin
treatment. One of the remaining patients who had posi-
tive stool toxin results on day 10 had achieved symptom
resolution 4 days after beginning rifaximin treatment and
remained symptom-free through the end of treatment;
further treatment was not administered, since symptom
resolution was achieved. The other patient was the woman
with endometrial cancer. In subsequent followup, and while
receiving chemotherapy, she was symptomatic and remained
positive forEIAforC.diﬃcile. Atthis point, oralvancomycin
therapy was provided for 14 days. In the 49-day followup for
this patient, she had become asymptomatic.
Of the 7 patients who achieved symptom resolution
within 10 days of rifaximin therapy, none had symptom
recurrence within 2 weeks after treatment, including the
patient who was asymptomatic despite positive stool toxin
results at the end of rifaximin treatment. The median long-
term followup available for the 7 patients who responded to
rifaximin treatment was 160 days (range, 36–261d). During
this period, 1 of these 7 patients experienced CDAD recur-
rence. This patient developed symptoms at followup day 50,
most likely as a complication of a prolonged hospitalization
for end-stage heart failure; CDAD was conﬁrmed by stool
EIA on day 52 and was treated with metronidazole.
4. Discussion
In this current prospective, open-label study, rifaximin
1200mg/dfor10daysdemonstratedafavorablesafetyproﬁle
and was an eﬀective initial therapy for CDAD in hospitalized
patients. All of the 8 patients included had symptom reso-
lution during the course of rifaximin treatment; 6 patients
had eradication of C. diﬃcile stool toxins. In all patients,
no drug-related adverse events were reported. The rifaximin
success rate in this study (86%) was similar to rates reported
in studies of vancomycin and metronidazole [11, 13, 16, 29].4 Gastroenterology Research and Practice
The ﬁndings presented in this study, including the
observation that 1 patient achieved symptom resolution
despite persistence of stool C. diﬃcile toxin, are corroborated
by a 1990 randomized, open-label study in which rifaximin
600mg/d administered for 10 days resolved diarrheal symp-
toms associated with CDAD in a mean of 4.9 days, eﬀective
in 9 of 10 patients. However, stool C. diﬃcile toxins persisted
longerthandiarrhealsymptoms(mean,8.1days)forpatients
in the rifaximin group [28]. Similar results were observed in
the group that received vancomycin 1g/d for 10 days, with
the exception of time to eradication of stool C. diﬃcile toxin,
which was signiﬁcantly shorter for patients who received
vancomycin(mean,4.8d;P<0.005)[28].Theﬁndingsfrom
this Italian study suggest the potential beneﬁt of rifaximin
for the treatment of CDAD, but the study is limited by small
sample size and lack of posttreatment followup data.
The current ﬁndings that hospitalized patients who
received a 10-day course of rifaximin were asymptomatic
during the long-term post treatment followup period of up
to 261 days provide the ﬁrst report that rifaximin may help
prevent posttreatment CDAD recurrences when adminis-
tered as ﬁrst-line therapy. Two previous open-label studies
that investigated the eﬃcacy of rifaximin for prevention of
CDAD recurrence focused on patients with recurrent CDAD
who had received prior systemic antibiotic treatment [24,
25].Rifaximin1200mg/dfor ≥2weeksfollowedbyrifaximin
600mg/d for 2 weeks resolved symptoms in a mean of 7.6
days and prevented recurrence for 1 month in 5 of 6 patients
with recurrent CDAD [24]. In addition, 7 of 8 patients with
recurrent CDAD who received rifaximin 400 to 800mg/d
for 2 weeks beginning immediately aftersuccessfultreatment
with vancomycin remained asymptomatic for 51 to 431 days
after treatment [25].
The current study has several strengths relative to previ-
ously published investigations, including the lack of van-
comycin or metronidazole treatment within 48 hours of
rifaximin treatment, all but one of these patients had no
history of CDAD, and the availability of long-duration
post treatment followup data. However, several limitations
warrant consideration, including the open-label design and
small sample size. The small number of enrolled patients,
which precluded randomization and comparison of rifax-
imin with standard therapies, is explained by diﬃculty
recruiting patients who met the inclusion criteria. Study
recruitment at the single hospital site depended on referrals
from hospital physicians, many of whom treated diarrheal
symptoms empirically before stool toxin test results were
available, thus limiting patient eligibility.
Despite these limitations, the current study provides
supportive evidence that the nonabsorbed antibiotic rifax-
imin may be eﬀective for the treatment of CDAD when
administered as initial therapy in previously uninfected
patients and may confer long-term protection against recur-
rence. Given that it has a favorable safety proﬁle and a
successratecomparabletopublishedratesforvancomycinor
metronidazole, rifaximin may oﬀer a promising alternative
tostandardtherapiesforCDAD.Anadditionalconsideration
for future studies would be related to cost of the therapy
and the indirect cost savings of adherence to a well-tolerated
therapy and prevention of recurrence. These encouraging
results, along with the increasing incidence and severity of
CDAD,suggestaneedforfurtherinvestigation.Randomized,
controlledtrialsarewarrantedtofurtherevaluatetheeﬃcacy
of rifaximin relative to current standard therapies and to
conﬁrm the role of rifaximin in the treatment of CDAD.
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